Common genetic variants in the glucocorticoid receptor and the 11β-hydroxysteroid dehydrogenase type 1 genes influence long-term cognitive impairments in patients with Cushing's syndrome in remission

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 9, 2014, Pages E1803-E1807

  Ragnarsson, Oskar ^a   Glad, Camilla A M ^a   Berglund, Peter ^a   Bergthorsdottir, Ragnhildur ^a   Eder, Derek N ^a   Johannsson, Gudmundur ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; GLUCOCORTICOID RECEPTOR; MINERALOCORTICOID RECEPTOR; MULTIDRUG RESISTANCE PROTEIN 1; NR3C1 PROTEIN, HUMAN; NR3C2 PROTEIN, HUMAN;

11BETAHSD1 GENE; ABCB1 GENE; ADULT; ARTICLE; ATTENTION; AUDITORY ATTENTION; AUDITORY SYSTEM FUNCTION; CASE CONTROL STUDY; COGNITIVE DEFECT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CUSHING SYNDROME; FATIGUE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NR3C1 GENE; NR3C2 GENE; READING; REMISSION; SINGLE NUCLEOTIDE POLYMORPHISM; SPEECH ARTICULATION; VISUAL ATTENTION; VISUAL SYSTEM FUNCTION; WORKING MEMORY; AGED; COGNITION; COGNITION DISORDERS; COMPLICATION; GENETICS; MIDDLE AGED; PHYSIOLOGY;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ADULT; AGED; CASE-CONTROL STUDIES; COGNITION; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; CUSHING SYNDROME; FEMALE; GENETIC VARIATION; HUMANS; MALE; MIDDLE AGED; RECEPTORS, GLUCOCORTICOID; RECEPTORS, MINERALOCORTICOID; REMISSION INDUCTION;

EID: 84907222974     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-1906     Document Type: Article

References (19)

1. Tiemensma J, Kokshoorn NE, Biermasz NR, et al. Subtle cognitive impairments in patients with long-term cure of Cushing's disease. J Clin Endocrinol Metab. 2010;95:2699-2714.
2. Resmini E, Santos A, Gomez-Anson B, et al. Verbal and visual memory performance and hippocampal volumes, measured by 3-Tesla magnetic resonance imaging, in patients with Cushing's syndrome. J Clin Endocrinol Metab. 2012;97:663-671.
3. Ragnarsson O, Berglund P, Eder DN, Johannsson G. Long-term cognitive impairments and attentional deficits in patients with Cushing's disease and cortisol-producing adrenal adenoma in remission. J Clin Endocrinol Metab. 2012;97:E1640-E1648.
4. Ragnarsson O, Berglund P, Eder DN, et al. Neurodegenerative and inflammatory biomarkers in cerebrospinal fluid in patients with Cushing's syndrome in remission. Eur J Endocrinol. 2013;169:211-215.
5. van Rossum EF, Lamberts SW. Polymorphisms in the glucocorticoid receptor gene and their associations with metabolic parameters and body composition. Recent Prog Horm Res. 2004;59:333-357.
6. Szappanos A, Patocs A, Toke J, et al. BclI polymorphism of the glucocorticoid receptor gene is associated with decreased bone mineral density in patients with endogenous hypercortisolism. Clin Endocrinol (Oxf). 2009;71:636-643.
7. Trementino L, Appolloni G, Concettoni C, Cardinaletti M, Boscaro M, Arnaldi G. Association of glucocorticoid receptor polymorphism A3669G with decreased risk of developing diabetes in patients with Cushing's syndrome. Eur J Endocrinol. 2012;166:35-42.
8. DeRijk RH, Wust S, Meijer OC, et al. A common polymorphism in the mineralocorticoid receptor modulates stress responsiveness. J Clin Endocrinol Metab. 2006;91:5083-5089.
9. Martinez F, Mansego ML, Escudero JC, Redon J, Chaves FJ. Association of a mineralocorticoid receptor gene polymorphism with hypertension in a Spanish population. Am J Hypertens. 2009;22: 649-655.
10. Dekker MJ, Tiemeier H, Luijendijk HJ, et al. The effect of common genetic variation in 11beta-hydroxysteroid dehydrogenase type 1 on hypothalamic-pituitary-adrenal axis activity and incident depression. J Clin Endocrinol Metab. 2012;97:E233-E237.
11. Lovas K, Gjesdal CG, Christensen M, et al. Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone. Eur J Endocrinol. 2009;160:993-1002.
12. Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis. 1994;18(suppl 1):S79-S83.
13. Asberg M, Montgomery SA, Perris C, Schalling D, Sedvall G. A comprehensive psychopathological rating scale. Acta Psychiatr Scand. 1978;(suppl):5-27.
14. Reitan R, Wolfson D. The Halstead-Reitan Neuropsychological Test Battery. Theory and Clinical Interpretation. Tucson, AZ: Neuropsychology Press; 1985.
15. Wechsler D. Wechsler Adult Intelligence Scale, 3rd ed. (WAIS-III NI). Stockholm: Harcourt Assessment; 2004.
16. Delis D, Kaplan E, Kramer J. Executive Function System-D-KEFS. San Antonio: Harcourt Assessment; 2001.
17. Järpsten B. DLS handledning för Skolår 7-9 och år 1 i Gymnasiet. Stockholm: Psykologförlaget; 2002.
18. Low SC, Moisan MP, Noble JM, Edwards CR, Seckl JR. Glucocorticoids regulate hippocampal 11α-hydroxysteroid dehydrogenase activity and gene expression in vivo in the rat. J Neuroendocrinol. 1994;6:285-290.
19. Esser C, Tomluk J. Reporting Hardy-Weinberg tests in case-control studies: reasons for caution but not for panic reactions. J Invest Dermatol. 2005;124:1082-1083.